Quarterly ResultMay 13, 2026, 08:02 AM
Century Therapeutics' CNTY-813 IND on track for 4Q 2026; Cash into 1Q 2029
AI Summary
Century Therapeutics reported Q1 2026 financial results and provided key business highlights. The company's lead program, CNTY-813 for type 1 diabetes, remains on track for IND submission in 4Q 2026, with initial clinical data expected in 2H 2027. Additionally, CNTY-308 is set to advance into clinical testing this year. Century Therapeutics maintains a strong financial position with $217.0 million in cash, cash equivalents, and marketable securities as of March 31, 2026, providing a cash runway into 1Q 2029. The company reported a net loss of $21.6 million for the quarter.
Key Highlights
- CNTY-813 IND submission expected in 4Q 2026.
- CNTY-813 initial clinical data anticipated in 2H 2027.
- CNTY-308 clinical trial planned to initiate in 2026.
- Cash, cash equivalents, and marketable securities were $217.0 million as of March 31, 2026.
- Cash runway extends into 1Q 2029.
- Q1 2026 net loss was $21.6 million, compared to $76.6 million net income in Q1 2025.
- Q1 2026 R&D expenses decreased to $17.1 million from $26.6 million in Q1 2025.
- Q1 2026 G&A expenses decreased to $6.6 million from $8.4 million in Q1 2025.